NEW YORK (GenomeWeb News) – Asterand said today that it has extended its drug-discovery and development collaboration with Bristol-Myers Squibb for up to three years.

Under the agreement, BMS will continue to have access to Asterand's PhaseZERO drug-discovery services and XpressBANK human tissue and clinical sample bank for early drug-target validation and compound optimization.

BMS may also use Asterand's ProCURE custom clinical sample collection service, Asterand said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.